Advertisement

Topics

3 Years/5 Years Long-time Follow-up of Kaletra After Failure of Primary Therapy

2014-08-27 03:15:19 | BioPortfolio

Summary

Development of resistance to protease inhibitors in patients under Kaletra as first or second-line therapy.

Description

Observational study to assess the Development of Resistance to Protease Inhibitors in Patients under Kaletra as first or second-line therapy. The study is investigating the following questions:

- Can development of resistance against Kaletra be observed?

- If yes, after what time period does the resistance occur?

- Which mutations are being selected?

- After virologic failure which other therapy regimens are effective?

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Conditions

Human Immunodeficiency Virus

Intervention

Lopinavir/Ritonavir (Kaletra)

Location

Site Reference ID/Investigator# 27963
Aachen
Germany
52062

Status

Active, not recruiting

Source

Abbott

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:15:19-0400

Clinical Trials [1676 Associated Clinical Trials listed on BioPortfolio]

3 Years Long-time Follow up of Kaletra Therapy

Long-term observation of therapy-naïve patients under Kaletra therapy.

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-in...

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Usage, dosing, tolerability, and effectiveness of Kaletra tablets in Human Immunodeficiency Virus-infected patients.

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)

The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same d...

Lopinavir/Ritonavir (Kaletra)PK

The objective of this study is to compare the pharmacokinetics of lopinavir tablets administered to pediatric patients as either whole or crushed tablets. The study is a randomized,open-la...

PubMed Articles [12988 Associated PubMed Articles listed on BioPortfolio]

Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.

In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus (HIV) infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonav...

An Innovative, Collaborative, and Strategic Approach to Proactively Evaluate and Update Drug Interactions Based on Prescribing Information of Newly Approved Medicinal Products.

Drug-drug interaction (DDIs) are evaluated using pharmacokinetic (PK) simulation models, clinical studies, and scientific publications throughout drug development. DDIs with Norvir (ritonavir) and com...

Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.

The emergence of drug-resistant HIV from a wide-spread anti-viral chemotherapy targeting HIV protease in the past decades is unavoidable and provides a challenge to develop alternative inhibitors. We ...

Simultaneous quantitation of zidovudine, efavirenz, lopinavir and ritonavir in human hair by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.

Nowadays, zidovudine, efavirenz, lopinavir and ritonavir are important components of the second-line antiretroviral therapeutic regimen of National Free Antiretroviral Treatment Program in China. The ...

Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children: 7-year follow-up of the IMPAACT P1060 trial.

To estimate the long-term metabolic effects of initiating a lopinavir/ritonavir (LPV/r)-based regimen as first-line therapy for HIV-infected children less than three years of age in resource-limited s...

Medical and Biotech [MESH] Definitions

Proteins encoded by the NEF GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Proteins encoded by the VPR GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Proteins encoded by the TAT GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Proteins encoded by the REV GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Proteins encoded by the VIF GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

More From BioPortfolio on "3 Years/5 Years Long-time Follow-up of Kaletra After Failure of Primary Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial